Abstracts tagged "ANCA"

Abstract Number: 1432 • ACR Convergence 2020
Thyroid Disease in Patients with ANCA-Associated Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹University of California Los Angeles, West Hills, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have found increased prevalence of thyroid disease in patients with ANCA-associated vasculitis (AAV), especially positive myeloperoxidase (MPO)-ANCA, but a majority of the…
Abstract Number: 1433 • ACR Convergence 2020
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
Anna Wilding¹, Rona Smith², David Jayne³, Mårten Segelmark⁴ and Aladdin Mohammad⁵, ¹Lund University, Staffanstorp, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, ⁵Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: A higher incidence of thyroid disease has been seen in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aim to assess the incidence…
Abstract Number: 1435 • ACR Convergence 2020
Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis
Yutaro Hayashi¹, Satoshi Hama², Keisuke Izumi², Mari Ushikubo¹, Misako Konishi³, Yutaka Okano⁴ and Hisaji Ohshima², ¹Tokyo medical center, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ³Tokyo medical center, toukyouto Meguroku, Japan, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: ANCA-associated vasculitis (AAV) sometimes presents mononeuritis multiplex which worsens the prognosis and activity of daily living in patients. This study aimed to determine theprognostic factorsand…
Abstract Number: 1439 • ACR Convergence 2020
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion², Marta Casal Moura¹, Amber Hummel¹, Eva Carmona¹, Tobias Peikert¹, Carol Langford³, Peter A. Merkel⁴, Paul Monach⁵, Philip Seo⁶, Robert Spiera⁷, Eugene St Clair⁸, Fernando C. Fervenza¹, Kristina Harris⁹, John H. Stone¹⁰, Jacques-Olivier Pers¹¹, Ulrich Specks¹ and Divi Cornec¹², ¹Mayo Clinic, Rochester, MN, ²Brest University, Brest, Bretagne, France, ³Cleveland Clinic, Moreland Hills, OH, ⁴Division of Rheumatology University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's, Boston, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁸Duke University, Durham, NC, ⁹Immune Tolerance Network, Bethesda, MD, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹University of Brest, Brest, France, ¹²Rheumatology Department, Brest University Hospital, Brest, France
Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…
Abstract Number: 1440 • ACR Convergence 2020
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Matthew Terrill¹, Hendrik Nel², Yassmin Musthaffa³, Wong Richard⁴, Ross Francis⁵, David Johnson⁵, Greg Keir⁶, David Gillis⁷ and Ranjeny Thomas⁸, ¹University of Queensland Diamantina Institute and Princess Alexandra Hospital, Rheumatology Department, Brisbane- Australia, Moffat beach, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Immunology Department, Princess Alexandra Hospital, Brisbane- Australia, Brisbane, Australia, ⁵Renal Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁶Respiratory Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁷Immunopathology Department, Royal Women’s and Children’s Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁸University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: In Myeloperoxidase (MPO) Anti Neutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (MPO-AAV), murine and human studies suggest that the MPO435-465 region, which includes ANCA-binding MPO447-459, the…
Abstract Number: 2049 • ACR Convergence 2020
Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis
Rennie Rhee¹, Jiarui Lu¹, Kyle Bittinger², Antoine Sreih¹, Jung-Jin Lee³, Lisa Mattei³, Brendan Kelly⁴, Peter C. Grayson⁵, Hongzhe Lee⁴, Ronald Collman⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Nasal bacteria have been linked to disease activity in granulomatosis with polyangiitis (GPA) with most studies focused on Staphylococcus aureus. Our previous study identified…
Abstract Number: 0281 • ACR Convergence 2020
ANCA in SLE: Prevalence and Predictor Factors
Reza Mirza¹, Murray Urowitz², Jiandong Su³ and Dafna Gladman⁴, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: SLE is a systemic autoimmune disease notable for the ability to affect nearly every tissue, and is associated with a breadth of auto-antibodies. Anti-neutrophilic…
Abstract Number: 1419 • ACR Convergence 2020
Clinical Disease Might Be Divided into Two Phenotypes in ANCA Associated Vasculitis; Results of a Cluster Analysis
Elif Ediboglu¹, Onay Gercik², Emre Bilgin³, Dilek Solmaz⁴, Irfan Ocal⁵, Arzu Saglam⁶, Zeki Soypacacı², Haluk Cinaklı⁵, Sedat Kiraz³, Ömer Karadağ⁷ and Servet Akar², ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Izmir, Turkey, ³Hacettepe University, Ankara, Turkey, ⁴Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ⁵Izmir Katip Celebi University, Izmir, ⁶Hacettepe University, Ankara, ⁷Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara,, Ankara, Turkey
Background/Purpose: One of the controversial matters in ANCA associated vasculitis is the definition of disease based on clinical characteristics since there is a remarkable overlap…
Abstract Number: 1420 • ACR Convergence 2020
Characterization of ANCA-Associated Vasculitis Among African American Patients
Sehris Khawaja¹, Saloni Godbole¹, Maryann Kimoto², Virginia Steen³ and Kaitlin Quinn⁴, ¹Georgetown University, Washington, DC, ²UCLA, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴National Institutes of Health, Washington, DC
Background/Purpose: ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by inflammation of small and medium-sized arteries. Prevalence and phenotype of these diseases appear to…
Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Linda Wagner-Weiner ¹, Vidya Sivaraman ², Karen James ³, Eric Yen ⁴, Kathleen O'Neil ⁵, Dana Gerstbacher ⁶, Ann Marie Szymanski⁷, Kimberly Morishita ⁸ and David Cabral ⁹ for the CARRA investigators, ¹University of Chicago, Chicago, Illinois, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³University of Utah, 84113, Utah, ⁴UCLA, Los Angeles, California, ⁵University of Indiana School of Medicine, Indianapolis, Indiana, ⁶Stanford University School of Medicine, Palo Alto, California, ⁷Tampa, Florida, ⁸University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, ⁹BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: 2629 • 2019 ACR/ARP Annual Meeting
Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Yoko Wada¹, Masanori Sudo ², Takeshi Kuroda ³, Masaaki Nakano ⁴ and Ichiei Narita ², ¹Niigata Rinko Hospital, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ³Health administration office, Niigata University, Niigata, Niigata, Japan, ⁴School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Niigata, Japan
Background/Purpose: The anti-neutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA), and eosinophilic granulomatosis with polyangitis (EGPA). These small-vessel…

« Previous Page
1
…
4
5
6
7
8
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].